See up to 3 months of ALMS. The 7-day demo opens the 1M and 3M ranges and puts ALMS on your watchlist.
Start 7-day demoLatest ALMS insider trades
Srinivas Akkaraju - DirectorOpen-market purchase$2.46M- Srinivas Akkaraju - DirectorOpen-market purchase
About ALUMIS INC. (ALMS)
ALUMIS INC. files with the SEC under CIK 0001847367 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
ALMS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 4 | 986,721 | $10.73M |
| Open-market sale | 8 | 111,084 | $1.41M |
ALMS insider transactions (Form 4)
5852 Form 4 filings on record, the earliest from May 6, 2025, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Srinivas Akkaraju - Director | Open-market purchase | Common Stock | 220,070 | $11.17 footnote F1 | $2.46M | |
| Srinivas Akkaraju - Director | Open-market purchase | Common Stock | 220,070 | $11.17 footnote F1 | $2.46M | |
| Srinivas Akkaraju - Director | Open-market sale | Common Stock | 48,066 | $10.55 footnote F5 | $507K | |
| Srinivas Akkaraju - Director | Open-market sale | Common Stock | 48,065 | $10.55 footnote F5 | $507K | |
| Srinivas Akkaraju - Director | Open-market purchase | Common Stock | 273,291 | $10.63 footnote F6 | $2.90M | |
| Srinivas Akkaraju - Director | Open-market purchase | Common Stock | 273,290 | $10.63 footnote F6 | $2.90M | |
| ||||||
| John R. Schroer - Officer | Open-market sale | Common Stock | 3,282 footnote F1 | $26.37 footnote F2 | $87K | |
| ||||||
 Sanam Pangali - Officer | Open-market sale | Common Stock | 1,364 footnote F1 | $26.37 footnote F2 | $36K | |
| ||||||
| Roy C. Hardiman - Officer | Open-market sale | Common Stock | 2,692 footnote F1 | $26.37 footnote F2 | $71K | |
| ||||||
| David M. Goldstein - Officer | Open-market sale | Common Stock | 2,596 footnote F1 | $26.37 footnote F2 | $68K | |
| ||||||
| Jorn Drappa - Officer | Open-market sale | Common Stock | 2,447 footnote F1 | $26.37 footnote F2 | $65K | |
| ||||||
 Mark Christopher Bradley - Officer | Open-market sale | Common Stock | 2,572 footnote F1 | $26.37 footnote F2 | $68K | |
| ||||||
| Sanam Pangali - Officer | Option exercise | Common Stock | 5,000 | $5.06 | $25K | |
| Sanam Pangali - Officer | Open-market sale | Common Stock | 5,000 | $28.00 | $140K | |
| Sanam Pangali - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| Lynn A. Tetrault | Grant or award | Common Stock | 3,553 footnote F1 | $0.00 | - | |
| Lynn A. Tetrault | Grant or award | Stock Option (Right to Buy) | 15,528 | $0.00 | - | |
| ||||||
| Zhengbin Yao | Grant or award | Common Stock | 3,553 footnote F1 | $0.00 | - | |
| Zhengbin Yao | Grant or award | Stock Option (Right to Buy) | 15,528 | $0.00 | - | |
| ||||||
| Sapna Srivastava | Grant or award | Common Stock | 3,553 footnote F1 | $0.00 | - | |
| Sapna Srivastava | Grant or award | Stock Option (Right to Buy) | 15,528 | $0.00 | - | |
| ||||||
| Patrick Machado | Grant or award | Stock Option (Right to Buy) | 15,528 | $0.00 | - | |
| Patrick Machado | Grant or award | Common Stock | 3,553 footnote F1 | $0.00 | - | |
| ||||||
| Srinivas Akkaraju | Grant or award | Stock Option (Right to Buy) | 15,528 | $0.00 | - | |
| Srinivas Akkaraju | Grant or award | Common Stock | 3,553 footnote F1 | $0.00 | - | |
| ||||||
| Jorn Drappa - Officer | Option exercise | Common Stock | 15,535 | $5.06 | $79K | |
| Jorn Drappa - Officer | Option exercise | Common Stock | 11,317 | $8.84 | $100K | |
| Jorn Drappa - Officer | Option exercise | Stock Option (Right to Buy) | 11,317 | $0.00 | - | |
| Jorn Drappa - Officer | Option exercise | Stock Option (Right to Buy) | 15,535 | $0.00 | - | |
| Foresite Labs, LLC - 10% Owner | Other | Common Stock | 1,176,470 | $0.00 | - | |
| Foresite Labs, LLC - 10% Owner | Other | Common Stock | 1,123,337 | $0.00 | - | |
| Foresite Labs, LLC - 10% Owner | Other | Common Stock | 1,123,337 | $0.00 | - | |
| Foresite Labs, LLC - 10% Owner | Other | Common Stock | 680,486 | $0.00 | - | |
| Foresite Capital Management VI LLC - 10% Owner | Other | Common Stock | 1,176,470 | $0.00 | - | |
| Foresite Capital Management VI LLC - 10% Owner | Other | Common Stock | 1,123,337 | $0.00 | - | |
| Foresite Capital Management VI LLC - 10% Owner | Other | Common Stock | 1,123,337 | $0.00 | - | |
| Foresite Capital Management VI LLC - 10% Owner | Other | Common Stock | 680,486 | $0.00 | - | |
| James B. Tananbaum - Director | Other | Common Stock | 1,176,470 | $0.00 | - | |
| James B. Tananbaum - Director | Other | Common Stock | 1,123,337 | $0.00 | - | |
| James B. Tananbaum - Director | Other | Common Stock | 1,123,337 | $0.00 | - | |
| James B. Tananbaum - Director | Other | Common Stock | 680,486 | $0.00 | - | |
| Sanam Pangali - Officer | Grant or award | Stock Option (Right to Buy) | 186,200 | $0.00 | - | |
| Martin Babler - Officer | Grant or award | Stock Option (Right to Buy) | 745,875 | $0.00 | - | |
| Roy C. Hardiman - Officer | Grant or award | Stock Option (Right to Buy) | 190,875 | $0.00 | - | |
| Mark Christopher Bradley - Officer | Grant or award | Stock Option (Right to Buy) | 190,225 | $0.00 | - | |
| Jorn Drappa - Officer | Grant or award | Stock Option (Right to Buy) | 221,450 | $0.00 | - | |
| John R. Schroer - Officer | Grant or award | Stock Option (Right to Buy) | 202,225 | $0.00 | - | |
| David M. Goldstein - Officer | Grant or award | Stock Option (Right to Buy) | 216,675 | $0.00 | - | |
| Srinivas Akkaraju | Open-market purchase | Common Stock | 588,235 | $17.00 | $10.00M | |
| Srinivas Akkaraju | Open-market purchase | Common Stock | 96,000 | $7.55 footnote F1 | $725K | |
| Srinivas Akkaraju | Open-market purchase | Common Stock | 100,000 | $7.75 footnote F3 | $775K | |
| Srinivas Akkaraju | Open-market purchase | Common Stock | 66,027 | $8.18 footnote F4 | $540K | |
| ||||||
| Srinivas Akkaraju | Open-market purchase | Common Stock | 48,537 | $7.64 footnote F1 | $371K | |
| Srinivas Akkaraju | Open-market purchase | Common Stock | 38,702 | $7.64 footnote F3 | $296K | |
| Srinivas Akkaraju | Open-market purchase | Common Stock | 86,350 | $7.46 footnote F4 | $644K | |
| ||||||
| Foresite Labs, LLC - 10% Owner | Open-market purchase | Common Stock | 72,212 | $7.38 | $533K | |
| Foresite Capital Management VI LLC - 10% Owner | Open-market purchase | Common Stock | 72,212 | $7.38 | $533K | |
| James B. Tananbaum - Director | Open-market purchase | Common Stock | 72,212 | $7.38 | $533K | |
Item 8.01, 9.01
Item 2.02, 9.01
Item 8.01, 9.01
Item 5.07
Recent ALMS Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
ALMS insider trading FAQ
What is the latest insider trade for ALMS?
ALUMIS INC. (ALMS) had 7 insider filings in the last 90 days, with the most recent on 2026-09-10. The full record for ALMS runs to 52 Form 4 filings, the earliest from 2025-05-06. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ALMS stock?
4 insider purchases of ALMS were filed in the last 90 days, totaling $10.73M.
How many insiders are selling ALMS stock?
8 insider sales of ALMS were filed in the last 90 days, totaling $1.41M.
Where can I see ALMS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ALMS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Srinivas Akkaraju view on EDGAR
- - John R. Schroer view on EDGAR
- - Sanam Pangali view on EDGAR
- - Roy C. Hardiman view on EDGAR
- - David M. Goldstein view on EDGAR
- - Jorn Drappa view on EDGAR
- - Mark Christopher Bradley view on EDGAR
- - Sanam Pangali view on EDGAR
- - Lynn A. Tetrault view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ALMS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ALMS with a 7-day demo
- ALMS on your watchlist
- Every ALMS Form 4 filing on record
- Up to 3 months of ALMS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
